Locus Biosciences

Executive Summary

Locus Biosciences is a clinical-stage biotechnology company pioneering AI-enabled precision medicine through engineered bacteriophage therapies. Based in Morrisville, North Carolina, the company leverages its proprietary LOCUS platform to design targeted treatments for bacterial infections and other diseases. Its lead program targets E. coli infections and is currently in Phase 2 development, with additional programs in immunology, oncology, and CNS disorders. Locus's approach offers a potential solution to antibiotic resistance by using highly specific bacteriophages to kill pathogenic bacteria without disrupting the microbiome. The company's AI-driven platform enables rapid design and optimization of phage cocktails, positioning it as a leader in the emerging field of precision phage therapy. With a strong intellectual property portfolio and a focus on unmet medical needs, Locus Biosciences represents a compelling investment opportunity in the microbiome and biologics space.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim data readout for lead E. coli program60% success
• Q3 2026Potential partnership or licensing deal for phage platform50% success
• Q1 2027FDA meeting or IND submission for new indication40% success